摘要
重组蛋白/多肽类药物在人体血清内半衰期较短,很大程度上限制了其临床应用。人血清白蛋白(HSA)具有半衰期长、生物相容性好、低免疫原性等优点,是理想的药物载体。各种基于HSA的蛋白质药物长效化技术得到了广泛的应用和发展,目前主要包括构建HSA融合蛋白,通过共价化学键与HSA偶联,通过非共价键与HSA可逆性结合。总结了近年来基于白蛋白药物长效化技术的发展,各项技术的优缺点及药物开发现状。
Recombinant protein and peptide drugs have a short half-life in human serum,which largely limits their clinical application.Human serum albumin(HSA)has the advantages of long half-life,good biocompatibility and low immunogenicity,which is an ideal drug carrier.Various albumin-based strategies have been widely used and developed to create long-lasting protein therapeutics.At present,it mainly includes the construction of HSA fusion proteins,coupling with HSA through covalent chemical bonds,and reversible binding to HSA through non-covalent bonds.The development of albumin-based technologies to create long-lasting protein therapeutics in recent years,the advantages and disadvantages of various technologies and the status of their applications in drug development were summarized.
作者
徐欢
周美玲
葛琳
王志明
Huan XU;Mei-ling ZHOU;Lin GE;Zhi-ming WANG(New Drug R&D Center,North China Pharmaceutical Corporation,Shijiazhuang 050015,China)
出处
《中国生物工程杂志》
CAS
CSCD
北大核心
2019年第1期82-89,共8页
China Biotechnology
基金
国家重大新药创制专项(2017ZX09303008)资助项目
关键词
白蛋白融合
连接肽
化学偶联
脂肪酸修饰
白蛋白结合肽
Albumin fusion
Linker
Chemical coupling
Modification with fatty acids
Albumin-binding peptide
作者简介
通讯作者:王志明,E-mail:wzm3994@163.com.
